Search

Your search keyword '"Kleymenov, Denis A."' showing total 22 results
Start Over Author "Kleymenov, Denis A."
22 results on '"Kleymenov, Denis A."'

2. Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization

Author

Karyagina, Anna S., Gromov, Alexander V., Grunina, Tatyana M., Lyaschuk, Alexander M., Poponova, Maria S., Kleymenov, Denis A., Strukova, Natalia V., Generalova, Maria S., Ryazanova, Anna V., Galushkina, Zoya M., Dobrynina, Olga Yu., Bolshakova, Tatyana N., Sergeeva, Maria V., Romanovskaya-Romanko, Ekaterina A., Krasilnikov, Igor V., Subbotina, Marina E., and Lunin, Vladimir G.

Published
2022
Full Text
View/download PDF

3. Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models.

Author

Mazunina, Elena P., Gushchin, Vladimir A., Bykonia, Evgeniia N., Kleymenov, Denis A., Siniavin, Andrei E., Kozlova, Sofia R., Mukasheva, Evgenya A., Shidlovskaya, Elena V., Kuznetsova, Nadezhda A., Usachev, Evgeny V., Zlobin, Vladimir I., Burtseva, Elena I., Ivanov, Roman A., Logunov, Denis Y., and Gintsburg, Alexander L.

Subjects
COMBINED vaccines, INFLUENZA A virus, H1N1 subtype, VACCINE effectiveness, VACCINE immunogenicity, SEASONAL influenza
Abstract

Background. The combined or multivalent vaccines are actively used in pediatric practice and offer a series of advantages, including a reduced number of injections and visits to the doctor, simplicity of the vaccination schedule and minimization of side effects, easier vaccine monitoring and storage, and lower vaccination costs. The practice of widespread use of the combined vaccines has shown the potential to increase vaccination coverage against single infections. The mRNA platform has been shown to be effective against the COVID-19 pandemic and enables the development of combined vaccines. There are currently no mRNA-based combined vaccines approved for use in humans. Some studies have shown that different mRNA components in a vaccine can interact to increase or decrease the immunogenicity and efficacy of the combined vaccine. Objectives. In the present study, we investigated the possibility of combining the mRNA vaccines, encoding seasonal influenza and SARS-CoV-2 antigens. In our previous works, both vaccine candidates have shown excellent immunogenicity and efficacy profiles in mice. Methods. The mRNA-LNPs were prepared by microfluidic mixing, immunogenicity in mice was assessed by hemagglutination inhibition assay, enzyme-linked immunoassay and virus neutralization assay. Immunological efficacy was assessed in a mouse viral challenge model. Results. In this work, we demonstrated that the individual mRNA components of the combined vaccine did not affect the immunogenicity level of each other. The combined vaccine demonstrated excellent protective efficacy, providing a 100% survival rate when mice were infected with the H1N1 influenza virus and reducing the viral load in the lungs. Four days after the challenge with SARS-CoV-2 EG.5.1.1., no viable virus and low levels of detectable viral RNA were observed in the lungs of vaccinated mice. Conclusions. The combination does not lead to mutual interference between the individual vaccines. We believe that such a combined mRNA-based vaccine could be a good alternative to separated human vaccinations for the prevention of COVID-19 and influenza. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Author

Mazunina, Elena P., primary, Gushchin, Vladimir A., additional, Kleymenov, Denis A., additional, Siniavin, Andrei E., additional, Burtseva, Elena I., additional, Shmarov, Maksim M., additional, Mukasheva, Evgenya A., additional, Bykonia, Evgeniia N., additional, Kozlova, Sofia R., additional, Evgrafova, Elina A., additional, Zolotar, Anastasia N., additional, Shidlovskaya, Elena V., additional, Kirillova, Elena S., additional, Krepkaia, Anastasiya S., additional, Usachev, Evgeny V., additional, Kuznetsova, Nadezhda A., additional, Ivanov, Igor A., additional, Dmitriev, Sergey E., additional, Ivanov, Roman A., additional, Logunov, Denis Y., additional, and Gintsburg, Alexander L., additional

Published
2024
Full Text
View/download PDF

5. Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins

Author

Bykonia, Evgeniia N., primary, Kleymenov, Denis A., additional, Gushchin, Vladimir A., additional, Siniavin, Andrei E., additional, Mazunina, Elena P., additional, Kozlova, Sofia R., additional, Zolotar, Anastasia N., additional, Usachev, Evgeny V., additional, Kuznetsova, Nadezhda A., additional, Shidlovskaya, Elena V., additional, Pochtovyi, Andrei A., additional, Kustova, Daria D., additional, Ivanov, Igor A., additional, Dmitriev, Sergey E., additional, Ivanov, Roman A., additional, Logunov, Denis Y., additional, and Gintsburg, Alexander L., additional

Published
2024
Full Text
View/download PDF

6. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A

Author

Panova, Eugenia A., primary, Kleymenov, Denis A., additional, Shcheblyakov, Dmitry V., additional, Bykonia, Evgeniia N., additional, Mazunina, Elena P., additional, Dzharullaeva, Alina S., additional, Zolotar, Anastasia N., additional, Derkaev, Artem A., additional, Esmagambetov, Ilias B., additional, Sorokin, Ivan I., additional, Usachev, Evgeny V., additional, Noskov, Anatoly N., additional, Ivanov, Igor A., additional, Zatsepin, Timofei S., additional, Dmitriev, Sergey E., additional, Gushchin, Vladimir A., additional, Naroditsky, Boris S., additional, Logunov, Denis Y., additional, and Gintsburg, Alexander L., additional

Published
2023
Full Text
View/download PDF

7. Post-Vaccination and Post-Infection Immunity to the Hepatitis B Virus and Circulation of Immune-Escape Variants in the Russian Federation 20 Years after the Start of Mass Vaccination

Author

Asadi Mobarkhan, Fedor A., primary, Manuylov, Victor A., additional, Karlsen, Anastasia A., additional, Kichatova, Vera S., additional, Potemkin, Ilya A., additional, Lopatukhina, Maria A., additional, Isaeva, Olga V., additional, Mullin, Eugeniy V., additional, Mazunina, Elena P., additional, Bykonia, Evgeniia N., additional, Kleymenov, Denis A., additional, Popova, Liubov I., additional, Gushchin, Vladimir A., additional, Tkachuk, Artem P., additional, Saryglar, Anna A., additional, Kravchenko, Irina E., additional, Sleptsova, Snezhana S., additional, Romanenko, Victor V., additional, Kuznetsova, Anna V., additional, Solonin, Sergey A., additional, Semenenko, Tatyana A., additional, Mikhailov, Mikhail I., additional, and Kyuregyan, Karen K., additional

Published
2023
Full Text
View/download PDF

8. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level

Author

Godkov, Mikhail A., primary, Ogarkova, Darya A., additional, Gushchin, Vladimir A., additional, Kleymenov, Denis A., additional, Mazunina, Elena P., additional, Bykonia, Evgeniia N., additional, Pochtovyi, Andrei A., additional, Shustov, Valeriy V., additional, Shcheblyakov, Dmitry V., additional, Komarov, Andrey G., additional, Tsibin, Alexander N., additional, Zlobin, Vladimir I., additional, Logunov, Denis Y., additional, and Gintsburg, Alexander L., additional

Published
2022
Full Text
View/download PDF

9. Geographic and Temporal Variability of Hepatitis E Virus Circulation in the Russian Federation

Author

Mikhailov, Mikhail I., primary, Karlsen, Anastasia A., additional, Potemkin, Ilya A., additional, Isaeva, Olga V., additional, Kichatova, Vera S., additional, Malinnikova, Elena Yu., additional, Asadi Mobarkhan, Fedor A., additional, Mullin, Eugeniy V., additional, Lopatukhina, Maria A., additional, Manuylov, Victor A., additional, Mazunina, Elena P., additional, Bykonia, Evgeniia N., additional, Kleymenov, Denis A., additional, Popova, Liubov I., additional, Gushchin, Vladimir A., additional, Tkachuk, Artem P., additional, Polyakov, Andrey D., additional, Eladly, Ahmed Mohammed, additional, Solonin, Sergey A., additional, Gordeychuk, Ilya V., additional, and Kyuregyan, Karen K., additional

Published
2022
Full Text
View/download PDF

10. Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus

Author

Gushchin, Vladimir A., primary, Ogarkova, Darya A., additional, Dolzhikova, Inna V., additional, Zubkova, Olga V., additional, Grigoriev, Igor V., additional, Pochtovyi, Andrei A., additional, Iliukhina, Anna A., additional, Ozharovskaia, Tatiana A., additional, Kuznetsova, Nadezhda A., additional, Kustova, Daria D., additional, Shelkov, Artem Y., additional, Zrelkin, Denis I., additional, Odintsova, Alina S., additional, Grousova, Daria M., additional, Kan, Vladislav Y., additional, Davtyan, Sona A., additional, Siniavin, Andrei E., additional, Belyaeva, Elizaveta D., additional, Botikov, Andrei G., additional, Bessonova, Arina A., additional, Vasilchenko, Lyudmila A., additional, Vasina, Daria V., additional, Kleymenov, Denis A., additional, Slutskiy, Egor A., additional, Tkachuk, Artem P., additional, Burgasova, Olga A., additional, Loginova, Svetlana Y., additional, Rozhdestvensky, Evgeny V., additional, Shcheblyakov, Dmitry V., additional, Tsibin, Alexander N., additional, Komarov, Andrey G., additional, Zlobin, Vladimir I., additional, Borisevich, Sergei V., additional, Naroditsky, Boris S., additional, Logunov, Denis Y., additional, and Gintsburg, Alexander L., additional

Published
2022
Full Text
View/download PDF

11. Geographic and Temporal Variability of Hepatitis E Virus Circulation in Non-Endemic Territories

Author

Mikhailov, Mikhail I., primary, Karlsen, Anastasia A., additional, Potemkin, Ilya A., additional, Isaeva, Olga V., additional, Kichatova, Vera S., additional, Malinnikova, Elena Yu., additional, Asadi Mobarkhan, Fedor A., additional, Mullin, Eugeniy V., additional, Lopatukhina, Maria A., additional, Manuylov, Victor, additional, Mazunina, Elena P., additional, Bykonia, Evgeniia N., additional, Kleymenov, Denis A., additional, Popova, Liubov I., additional, Gushchin, Vladimir A., additional, Tkachuk, Artem P., additional, Polyakov, Andrey D., additional, El-Adly, Ahmed M., additional, Solonin, Sergey A., additional, Gordeychuk, Ilya, additional, and Kyuregyan, Karen, additional

Published
2022
Full Text
View/download PDF

12. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A

Author

Panova, Eugenia A., primary, Kleymenov, Denis A., additional, Shcheblyakov, Dmitry V., additional, Bykonia, Evgeniia N., additional, Mazunina, Elena P., additional, Dzharullaeva, Alina S., additional, Zolotar, Anastasia N., additional, Derkaev, Artem A., additional, Esmagambetov, Ilias B., additional, Sorokin, Ivan I., additional, Usachev, Evgeny V., additional, Ivanov, Igor A., additional, Zatsepin, Timofei S, additional, Dmitriev, Sergey E., additional, Gushchin, Vladimir A., additional, Logunov, Denis Y., additional, and Gintsburg, Alexander L., additional

Published
2022
Full Text
View/download PDF

13. Dynamic Changes in Hepatitis A Immunity in Regions with Different Vaccination Strategies and Different Vaccination Coverage

Author

Kyuregyan, Karen K., primary, Lopatukhina, Maria A., additional, Asadi Mobarkhan, Fedor A., additional, Kichatova, Vera S., additional, Potemkin, Ilya A., additional, Isaeva, Olga V., additional, Karlsen, Anastasia A., additional, Malinnikova, Elena Yu., additional, Kaira, Alla N., additional, Kozhanova, Tatyana V., additional, Manuylov, Victor A., additional, Mazunina, Elena P., additional, Bykonia, Evgeniia N., additional, Kleymenov, Denis A., additional, Ignateva, Margarita E., additional, Trotsenko, Olga E., additional, Kuznetsova, Anna V., additional, Saryglar, Anna A., additional, Oorzhak, Natalia D., additional, Romanenko, Victor V., additional, and Mikhailov, Mikhail I., additional

Published
2022
Full Text
View/download PDF

14. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance

Author

Shkoda, Andrey S., primary, Gushchin, Vladimir A., additional, Ogarkova, Darya A., additional, Stavitskaya, Svetlana V., additional, Orlova, Olga E., additional, Kuznetsova, Nadezhda A., additional, Keruntu, Elena N., additional, Pochtovyi, Andrei A., additional, Pukhov, Alexander V., additional, Kleymenov, Denis A., additional, Krzhanovsky, Vasyli G., additional, Vasina, Daria V., additional, Shkuratova, Nataliya V., additional, Shidlovskaya, Elena V., additional, Gorbunov, Alexey L., additional, Kustova, Daria D., additional, Mazurina, Evgeniya A., additional, Kozlova, Sofya R., additional, Soboleva, Alexandra V., additional, Grigoriev, Igor V., additional, Pankratyeva, Lyudmila L., additional, Odintsova, Alina S., additional, Belyaeva, Elizaveta D., additional, Bessonova, Arina A., additional, Vasilchenko, Lyudmila A., additional, Lupu, Igor P., additional, Adgamov, Ruslan R., additional, Tkachuk, Artem P., additional, Tokarskaya, Elizaveta A., additional, Logunov, Denis Y., additional, and Gintsburg, Alexander L., additional

Published
2022
Full Text
View/download PDF

15. Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection

Author

Manuylov, Victor, primary, Burgasova, Olga, additional, Borisova, Olga, additional, Smetanina, Svetlana, additional, Vasina, Daria, additional, Grigoriev, Igor, additional, Kudryashova, Alexandra, additional, Semashko, Maria, additional, Cherepovich, Bogdan, additional, Kharchenko, Olga, additional, Kleymenov, Denis, additional, Mazunina, Elena, additional, Tkachuk, Artem, additional, and Gushchin, Vladimir, additional

Published
2022
Full Text
View/download PDF

16. Geographic and Temporal Variability of Hepatitis E Virus Circulation in the Russian Federation.

Author

Mikhailov, Mikhail I., Karlsen, Anastasia A., Potemkin, Ilya A., Isaeva, Olga V., Kichatova, Vera S., Malinnikova, Elena Yu., Asadi Mobarkhan, Fedor A., Mullin, Eugeniy V., Lopatukhina, Maria A., Manuylov, Victor A., Mazunina, Elena P., Bykonia, Evgeniia N., Kleymenov, Denis A., Popova, Liubov I., Gushchin, Vladimir A., Tkachuk, Artem P., Polyakov, Andrey D., Eladly, Ahmed Mohammed, Solonin, Sergey A., and Gordeychuk, Ilya V.

Subjects
HEPATITIS E virus, SWINE farms, POPULATION dynamics, SWINE breeding, REPRODUCTION, VIRAL shedding, SEROPREVALENCE, GENETIC variation
Abstract

The factors influencing hepatitis E virus (HEV) circulation remain largely unexplored. We investigated HEV seroprevalence in humans and the prevalence of infection in farm pigs and rabbits in different regions of the Russian Federation, as well as the genetic diversity and population dynamics of the HEV. The anti-HEV IgG antibody detection rates in the general population increase significantly with age, from 1.5% in children and adolescents under 20 years old to 4.8% in adults aged between 20 and 59 years old to 16.7% in people aged 60 years and older. HEV seroprevalence varies between regions, with the highest rate observed in Belgorod Region (16.4% compared with the national average of 4.6%), which also has the country's highest pig population. When compared with the archival data, both increases and declines in HEV seroprevalence have been observed within the last 10 years, depending on the study region. Virus shedding has been detected in 19 out of the 21 pig farms surveyed. On one farm, the circulation of the same viral strain for five years was documented. All the human and animal strains belonged to the HEV-3 genotype, with its clade 2 sequences being predominant in pigs. The sequences are from patients, pigs, and sewage from pig farms clustered together, suggesting a zoonotic infection in humans and possible environmental contamination. The HEV-3 population size that was predicted using SkyGrid reconstruction demonstrated exponential growth in the 1970s–1990s, with a subsequent decline followed by a short rise around the year 2010, the pattern being similar to the dynamics of the pig population in the country. The HEV-3 reproduction number (Re) that was predicted using birth–death skyline analysis has fluctuated around 1 over the past 20 years in Russia but is 10 times higher in Belgorod Region. In conclusion, the HEV-3 circulation varies both geographically and temporally, even within a single country. The possible factors contributing to this variability are largely related to the circulation of the virus among farm pigs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level.

Author

Godkov, Mikhail A., Ogarkova, Darya A., Gushchin, Vladimir A., Kleymenov, Denis A., Mazunina, Elena P., Bykonia, Evgeniia N., Pochtovyi, Andrei A., Shustov, Valeriy V., Shcheblyakov, Dmitry V., Komarov, Andrey G., Tsibin, Alexander N., Zlobin, Vladimir I., Logunov, Denis Y., and Gintsburg, Alexander L.

Subjects
COVID-19 vaccines, BOOSTER vaccines, IMMUNOGLOBULIN G, COVID-19, IMMUNOGLOBULINS
Abstract

Vaccination against COVID-19 has occurred in Russia for more than two years. According to the Russian official clinical guidelines to maintain tense immunity in the conditions of the ongoing COVID-19 pandemic, it is necessary to use booster immunization six months after primary vaccination or a previous COVID-19 contraction. It is especially important to ensure the maintenance of protective immunity in the elderly, who are at risk of severe courses of COVID-19. Meanwhile, the immunological effectiveness of the booster doses has not been sufficiently substantiated. To investigate the immunogenicity of Sputnik V within the recommended revaccination regimen and evaluate the effectiveness of booster doses, we conducted this study on 3983 samples obtained from individuals previously vaccinated with Sputnik V in Moscow. We analyzed the level of antibodies in BAU/mL three times: (i) six months after primary immunization immediately before the booster (RV), (ii) 3 weeks after the introduction of the first component of the booster (RV1), and (iii) 3 weeks after the introduction of the second component of the booster (RV2). Six months after the primary vaccination with Sputnik V, 95.5% of patients maintained a positive level of IgG antibodies to the receptor-binding domain (RBD) of SARS-CoV-2. The degree of increase in the specific virus-neutralizing antibodies level after revaccination increased with a decrease in their initial level just before the booster dose application. In the group of people with the level of antibodies up to 100 BAU/mL six months after the vaccination, a more than eightfold increase (p < 0.001, Wilcoxon criterion with Bonferroni adjustment) in the level of specific antibodies was observed (Me = 8.84 (IQR: 3.63–30.61)). A significant increase in the IgG level after receiving both the first and the second booster doses occurred at the initial titer level up to 300 BAU/ mL (p < 0.001) in those who did not contract COVID-19 in the past and up to 100 BAU/mL (p < 0.001) in those who were previously infected with SARS-CoV-2. A significant increase in the antibody level after the first dose of the booster was noted for people who had up to 500 BAU/mL (p < 0.05), regardless of the previous COVID-19 infection. Thus, revaccination is most effective in individuals with an antibody level below 500 BAU/mL, regardless of the vaccinee age and COVID-19 contraction. For the first time, it has been shown that a single booster dose of the Sputnik vaccine is sufficient to form a protective immunity in most vaccinees regardless of age and preexisting antibody level. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels

Author

Kleymenov, Denis A., primary, Bykonia, Evgeniia N., additional, Popova, Liubov I., additional, Mazunina, Elena P., additional, Gushchin, Vladimir A., additional, Kolobukhina, Liudmila V., additional, Burgasova, Olga A., additional, Kruzhkova, Irina S., additional, Kuznetsova, Nadezhda A., additional, Shidlovskaya, Elena V., additional, Divisenko, Elizaveta V., additional, Pochtovyi, Andrei A., additional, Bacalin, Valeria V., additional, Smetanina, Svetlana V., additional, Tkachuk, Artem P., additional, Logunov, Denis Y., additional, and Gintsburg, Alexander L., additional

Published
2021
Full Text
View/download PDF

19. One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow

Author

Dolzhikova, Inna V, primary, Gushchin, Vladimir A, additional, Shcheblyakov, Dmitry V, additional, Tsybin, Alexander N., additional, Shchetinin, Alexey M, additional, Pochtovyi, Andrey A, additional, Komissarov, Andrey B, additional, Kleymenov, Denis A., additional, Kuznetsova, Nadezhda A, additional, Tukhvatulin, Amir I, additional, Zubkova, Olga V, additional, Dzharullaeva, Alina S, additional, Kovyrshina, Anna V, additional, Lubenets, Nadezhda L, additional, Grousova, Daria M, additional, Erokhova, Alina S, additional, Izhaeva, Fatima M, additional, Popova, Olga, additional, Ozharovskaya, Tatiana A, additional, Semikhin, Alexander S, additional, Tokarskaya, Elizaveta A, additional, Shmarov, Maksim M, additional, Nikitenko, Natalia A, additional, Shidlovskaya, Elena V, additional, Bykonia, Evgeniia N., additional, Mazunina, Elena P., additional, Divisenko, Elizaveta V, additional, Vasilchenko, Lyudmila A, additional, Popova, Liubov I., additional, Danilenko, Daria M, additional, Lioznov, Dmitry A, additional, Tkachuk, Artem P, additional, Borisevich, Sergei V, additional, Naroditsky, Boris S, additional, Logunov, Denis Y, additional, and Gintsburg, Alexander L, additional

Published
2021
Full Text
View/download PDF

20. Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study

Author

Tkachuk, Artem P., primary, Bykonia, Evgeniia N., additional, Popova, Liubov I., additional, Kleymenov, Denis A., additional, Semashko, Maria A., additional, Chulanov, Vladimir P., additional, Fitilev, Sergey B., additional, Maksimov, Semyon L., additional, Smolyarchuk, Elena A., additional, Manuylov, Victor A., additional, Vasina, Daria V., additional, Gushchin, Vladimir A., additional, and Gintsburg, Alexander L., additional

Published
2020
Full Text
View/download PDF

22. First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment.

Author

Vasina, Daria V., Kleymenov, Denis A., Manuylov, Victor A., Mazunina, Elena P., Koptev, Egor Yu., Tukhovskaya, Elena A., Murashev, Arkady N., Gintsburg, Alexander L., Gushchin, Vladimir A., and Tkachuk, Artem P.

Subjects
TUBERCULOSIS vaccines, MYCOBACTERIUM tuberculosis, DEXTRAN, CHIMERIC proteins
Abstract

Tuberculosis is known to be the biggest global health problem, causing the most deaths by a single infectious agent. Vaccine-development efforts are extremely important. This paper represents the results of the first-in-human trial of recombinant subunit tuberculosis vaccine GamTBvac in a Phase I study. GamTBvac is a new BCG booster candidate vaccine containing dextran-binding domain modified Ag85a and ESAT6-CFP10 MTB antigens and CpG ODN adjuvant, formulated with dextrans. Safety and immunogenicity of GamTBvac were estimated in an open-label clinical trial on 60 Mycobacterium tuberculosis uninfected (MTB-uninfected) volunteers previously-vaccinated with Bacillus Calmette—Guérin vaccine (BCG). The candidate vaccine had an acceptable safety profile and was well-tolerated. Three different vaccine doses with a double-immunization scheme were assessed for immunogenicity and induced a significant increase in IFN-γ in-house IGRA response and IgG ELISA analysis. Among them, the half dose vaccine group (containing DBD-ESAT6-CFP10, 12.5 μg; DBD-Ag85a, 12.5 μg; CpG (ODN 2216), 75 μg; DEAE-Dextran 500 kDa, 250 μg; and Dextran 500 kDa, 5 mg) provided high, early and stable in time immune response specific to both protein antigen fusions and is proposed for the further studies. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results